Patents by Inventor Nicholas Stuart Wilson

Nicholas Stuart Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 12246066
    Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: March 21, 2023
    Date of Patent: March 11, 2025
    Assignees: AGENUS INC., Ludwig Institute for Cancer Research Ltd., Memorial Sloan Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 12187795
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: January 7, 2025
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Anti-TIM-3 antibodies and methods of use thereof
    Patent number: 12011481
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM 3 and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: June 18, 2024
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • ANTI-TIM-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240181048
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: October 26, 2023
    Publication date: June 6, 2024
    Inventors: Marc VAN DIJK, Ekaterina Vladimirovna BREOUS-NYSTROM, Nicholas Stuart WILSON, Jeremy Dale WAIGHT, Dennis John UNDERWOOD
  • Antibodies and methods of use thereof
    Patent number: 11993653
    Abstract: Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 28, 2024
    Assignees: AGENUS INC., Ludwig Institute for Cancer Research Ltd., Memorial Sloan Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Roberta Zappasodi, Rikke Baek Holmgaard, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • Anti-lag-3 antibodies and methods of use thereof
    Patent number: 11993651
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 28, 2024
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240141047
    Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: September 27, 2023
    Publication date: May 2, 2024
    Inventors: Dhan Sidhartha CHAND, Nicholas Stuart WILSON, Dennis John UNDERWOOD, Benjamin Maxime Morin
  • Anti-TIM-3 antibodies and methods of use thereof
    Patent number: 11839653
    Abstract: Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: December 12, 2023
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Anti-CD73 antibodies and methods of use thereof
    Patent number: 11692042
    Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: July 4, 2023
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 11638755
    Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: May 2, 2023
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220372149
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: May 9, 2022
    Publication date: November 24, 2022
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, Jedd David WOLCHOK, Taha MERGHOUB, Roberta ZAPPASODI, Rikke Baek HOLMGAARD, David SCHAER, David Adam SAVITSKY, Nicholas Stuart WILSON
  • ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220267443
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: January 24, 2022
    Publication date: August 25, 2022
    Inventors: Marc Van DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, David Adam SAVITSKY, Nicholas Stuart WILSON
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220235349
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 30, 2021
    Publication date: July 28, 2022
    Inventors: Yanping Xiao, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 11345755
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: May 31, 2022
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220106581
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: July 19, 2021
    Publication date: April 7, 2022
    Applicants: AGENUS INC., AGENUS INC.
    Inventors: Yanping XIAO, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220089732
    Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 26, 2021
    Publication date: March 24, 2022
    Inventors: Dhan Sidhartha CHAND, Nicholas Stuart WILSON, Dennis John UNDERWOOD, Benjamin Maxime MORIN
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 11267889
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 8, 2022
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
  • Anti-CD137 antibodies and methods of use thereof
    Patent number: 11242385
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 8, 2022
    Assignee: AGENUS INC.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • Anti-CD137 antibodies and methods of use thereof
    Patent number: 11098117
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 24, 2021
    Assignee: Agenus Inc.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • ANTI-TIM-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210252139
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: January 12, 2021
    Publication date: August 19, 2021
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood